NCT05172050 - Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

June 12, 2021

Study Completion Date

June 12, 2021

Conditions

SARS CoV 2 Infection

Interventions

DRUG

Raloxifene

Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.

OTHER

Placebo

Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)

Trial Locations (11)

Unknown

CHU Amiens, Amiens

Clinique de l'infirmerie protestante de Lyon, Caluire-et-Cuire

CH Emile Roux le Puy en Velay, Le Puy-en-Velay

Centre Hospitalier de Troyes, Troyes

Humanitas Gavazzeni, Bergamo

Ospedale San Salvatore, L’Aquila

AO dei Colli (Ospedale Monaldi), Napoli

INMI Lazzaro Spallanzani, Roma

Istituto Clinico Humanitas, Rozzano

A.O.U. Città della Salute e della Scienza, Torino

Hospital Universitario Virgen de la Victoria, Málaga

All Listed Sponsors

lead

Dompé Farmaceutici S.p.A

INDUSTRY